Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 132, Issue 21
November 22 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Is less equal with ibrutinib dose?
Clinical Trials & Observations
Kerry A. Rogers
View Articletitled, Is less equal with ibrutinib dose?
Lymphoid Neoplasia
γδ T cells for immunotherapy
Meixiao Long
View Articletitled, γδ T cells for immunotherapy
Lymphoid Neoplasia
A small change makes a big difference in Hodgkin lymphoma
Martin Hutchings
View Articletitled, A small change makes a big difference in Hodgkin lymphoma
Red Cells, Iron, and Erythropoiesis
Tfr2 suppression benefits β-thalassemic erythropoiesis
Yelena Z. Ginzburg,Robert E. Fleming
View Articletitled, <em>Tfr2</em> suppression benefits β-thalassemic erythropoiesis
THROMBOSIS AND HEMOSTASIS
Postthrombotic syndrome: simple prevention
Susan Solymoss
View Articletitled, Postthrombotic syndrome: simple prevention

REVIEW ARTICLES

Anticoagulating patients with high-risk acquired thrombophilias
Leslie Skeith
View Articletitled, Anticoagulating patients with high-risk acquired thrombophilias
Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions
Sara R. Vazquez
View Articletitled, Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions

CLINICAL TRIALS AND OBSERVATIONS

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
Clinical Trials & Observations
Han W. Tun,Patrick B. Johnston,Lisa M. DeAngelis,Pamela J. Atherton,Levi D. Pederson,Patricia A. Koenig,Craig B. Reeder,Antonio M. Padula Omuro,David Schiff,Brian O’Neill,Jose Pulido,Kurt A. Jaeckle,Christian Grommes,Thomas E. Witzig
View Articletitled, Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
Supplemental data
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Clinical Trials & Observations
Lisa S. Chen,Prithviraj Bose,Nichole D. Cruz,Yongying Jiang,Qi Wu,Philip A. Thompson,Shuju Feng,Michael H. Kroll,Wei Qiao,Xuelin Huang,Nitin Jain,William G. Wierda,Michael J. Keating,Varsha Gandhi
View Articletitled, A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Supplemental data

LYMPHOID NEOPLASIA

Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib
Iris de Weerdt,Tom Hofland,Roeland Lameris,Sanne Endstra,Aldo Jongejan,Perry D. Moerland,Renee C. G. de Bruin,Ester B. M. Remmerswaal,Ineke J. M. ten Berge,Nora Liu,Mario van der Stelt,Laura M. Faber,Mark-David Levin,Eric Eldering,Sanne H. Tonino,Tanja D. de Gruijl,Hans J. van der Vliet,Arnon P. Kater
View Articletitled, Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib
Supplemental data
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma
Clinical Trials & Observations
Carsten Kobe,Helen Goergen,Christian Baues,Georg Kuhnert,Conrad-Amadeus Voltin,Josée Zijlstra,Otto Hoekstra,Jasmin Mettler,Alexander Drzezga,Andreas Engert,Peter Borchmann,Markus Dietlein
View Articletitled, Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma
IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas
Brief Report
Rabea Wagener,Cristina López,Kortine Kleinheinz,Julia Bausinger,Sietse M. Aukema,Inga Nagel,Umut H. Toprak,Julian Seufert,Janine Altmüller,Holger Thiele,Christof Schneider,Julia Kolarova,Jeongbin Park,Daniel Hübschmann,Eva M. Murga Penas,Hans G. Drexler,Andishe Attarbaschi,Randi Hovland,Eigil Kjeldsen,Michael Kneba,Udo Kontny,Laurence de Leval,Peter Nürnberg,Ilske Oschlies,David Oscier,Brigitte Schlegelberger,Stephan Stilgenbauer,Wilhelm Wössmann,Matthias Schlesner,Birgit Burkhardt,Wolfram Klapper,Elaine S. Jaffe,Ralf Küppers,Reiner Siebert
View Articletitled, IG-<em>MYC</em><sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas
Supplemental data

MYELOID NEOPLASIA

SKI controls MDS-associated chronic TGF-β signaling, aberrant splicing, and stem cell fitness
e-blood
David E. Muench,Kyle Ferchen,Chinavenmeni S. Velu,Kith Pradhan,Kashish Chetal,Xiaoting Chen,Matthew T. Weirauch,Clemencia Colmenares,Amit Verma,Nathan Salomonis,H. Leighton Grimes
View Articletitled, <em>SKI</em> controls MDS-associated chronic TGF-β signaling, aberrant splicing, and stem cell fitness
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model
Irene Artuso,Maria Rosa Lidonnici,Sandro Altamura,Giacomo Mandelli,Mariateresa Pettinato,Martina U. Muckenthaler,Laura Silvestri,Giuliana Ferrari,Clara Camaschella,Antonella Nai
View Articletitled, Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model
Supplemental data

THROMBOSIS AND HEMOSTASIS

Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis
Clinical Trials & Observations
Elham E. Amin,Ingrid M. Bistervels,Karina Meijer,Lidwine W. Tick,Saskia Middeldorp,Guy Mostard,Marlène van de Poel,Erik H. Serné,Hans M. Otten,Edith M. Klappe,Manuela A. Joore,Hugo ten Cate,Marije ten Wolde,Arina J. ten Cate-Hoek
View Articletitled, Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis

LETTERS TO BLOOD

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma
Clinical Trials & Observations
François Lemonnier,Jehan Dupuis,Pierre Sujobert,Olivier Tournillhac,Morgane Cheminant,Clémentine Sarkozy,Laura Pelletier,Ambroise Marçais,Cyrielle Robe,Virginie Fataccioli,Corinne Haioun,Olivier Hermine,Philippe Gaulard,Richard Delarue
View Articletitled, Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma
Supplemental data
Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes
Yasunobu Nagata,Satoshi Narumi,Yihong Guan,Bartlomiej P. Przychodzen,Cassandra M. Hirsch,Hideki Makishima,Hirohito Shima,Mai Aly,Victor Pastor,Teodora Kuzmanovic,Tomas Radivoyevitch,Vera Adema,Hassan Awada,Kenichi Yoshida,Samuel Li,Francesc Sole,Rabi Hanna,Babal K. Jha,Thomas LaFramboise,Seishi Ogawa,Mikkael A. Sekeres,Marcin W. Wlodarski,Jörg Cammenga,Jaroslaw P. Maciejewski
View Articletitled, Germline loss-of-function <em>SAMD9</em> and <em>SAMD9L</em> alterations in adult myelodysplastic syndromes
Supplemental data

BLOOD WORK

Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes
Wei Jiang,Szu-Hee Lee
View Articletitled, Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes
All Issues

Advertisement intended for health care professionals

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads
Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
Leukemic myeloblasts with erythrophagocytosis

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals